{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:14:45Z","timestamp":1762506885586},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T00:00:00Z","timestamp":1473206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thegreenjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.radonc.2016.08.026","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T19:45:18Z","timestamp":1474055118000},"page":"118-123","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Who will benefit most from hydrogel rectum spacer implantation in prostate cancer radiotherapy? A model-based approach for patient selection"],"prefix":"10.1016","volume":"121","author":[{"given":"Ben G.L.","family":"Vanneste","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aswin L.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emile N","family":"van Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lien","family":"Van De Voorde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pinkawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Lambin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2016.08.026_b0005","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.radonc.2014.10.014","article-title":"Rectal toxicity after intensity modulated radiotherapy for prostate cancer: which rectal dose volume constraints should we use?","volume":"113","author":"Fonteyne","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0010","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2015.12.020","article-title":"Dose-escalation of five-fraction SABR in prostate cancer: toxicity comparison of two prospective trials","volume":"118","author":"Musunuru","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0015","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00384-015-2289-4","article-title":"Chronic radiation proctitis: tricks to prevent and treat","volume":"30","author":"Vanneste","year":"2015","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.radonc.2016.08.026_b0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2013.02.004","article-title":"Application of anorectal sparing devices in prostate radiotherapy","volume":"106","author":"Smeenk","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0025","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.radonc.2011.09.005","article-title":"Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer","volume":"100","author":"Pinkawa","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.radonc.2013.01.007","article-title":"Interstitial biodegradable balloon for reduced rectal dose during prostate radiotherapy: results of a virtual planning investigation based on the pre- and post-implant imaging data of an international multicenter study","volume":"106","author":"Melchert","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijrobp.2007.02.034","article-title":"Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients","volume":"69","author":"Prada","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.026_b0040","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.ijrobp.2011.02.034","article-title":"Human collagen injections to reduce rectal dose during radiotherapy","volume":"82","author":"Noyes","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.026_b0045","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2009.05.069","article-title":"Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer","volume":"77","author":"Wilder","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.026_b0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.radonc.2012.11.009","article-title":"Low rectal toxicity after dose escalated IMRT treatment of prostate cancer using an absorbable hydrogel for increasing and maintaining space between the rectum and prostate: results of a multi-institutional phase II trial","volume":"106","author":"Uhl","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0055","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijrobp.2012.12.019","article-title":"A multi-institutional clinical trial of rectal dose reduction via injected polyethylene\u2013glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes","volume":"87","author":"Song","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.026_b0060","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.radonc.2014.02.011","article-title":"A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy\u00b1intensity modulated radiation therapy","volume":"111","author":"Strom","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0065","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ijrobp.2015.04.030","article-title":"Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy","volume":"92","author":"Mariados","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.026_b0070","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.radonc.2015.01.005","article-title":"Spacers in radiotherapy treatment of prostate cancer: is reduction of toxicity cost-effective?","volume":"114","author":"Vanneste","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrclinonc.2012.196","article-title":"Predicting outcomes in radiation oncology-multifactorial decision support systems","volume":"10","author":"Lambin","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0080","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ijrobp.2007.11.037","article-title":"Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT","volume":"71","author":"Valdagni","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.026_b0085","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.ijrobp.2011.03.028","article-title":"Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome","volume":"82","author":"Valdagni","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.026_b0090","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00066-012-0172-6","article-title":"Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer. Matched-pair analysis","volume":"188","author":"Pinkawa","year":"2012","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2016.08.026_b0095","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2016.08.026_b0100","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.urology.2007.03.042","article-title":"Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005","volume":"69","author":"Makarov","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2016.08.026_b0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1748-717X-3-38","article-title":"Pre-segmented 2-Step IMRT with subsequent direct machine parameter optimisation \u2013 a planning study","volume":"3","author":"Bratengeier","year":"2008","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0110","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","article-title":"Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial","volume":"53","author":"Pollack","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.026_b0115","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.08.002","article-title":"RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer","volume":"74","author":"Lawton","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.026_b0120","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ijrobp.2008.02.073","article-title":"Update of Dutch multicenter dose escalation trial of radiotherapy for localized prostate cancer","volume":"72","author":"Al-Mamgani","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.026_b0125","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ijrobp.2007.11.044","article-title":"Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer","volume":"70","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.026_b0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.026_b0135","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.eururo.2013.02.001","article-title":"Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity","volume":"64","author":"Ghadjar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2016.08.026_b0140","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial","volume":"16","author":"Aluwini","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0145","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.radonc.2009.08.004","article-title":"Dose-volume effects for normal tissues in external radiotherapy: pelvis","volume":"93","author":"Fiorino","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0150","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijrobp.2014.06.044","article-title":"Optimization of radiation therapy techniques for prostate cancer with prostate-rectum spacers: a systematic review","volume":"90","author":"Mok","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.026_b0155","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2217\/fon.13.223","article-title":"Spacer application for prostate cancer radiation therapy","volume":"10","author":"Pinkawa","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0160","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.clon.2014.09.008","article-title":"The REQUITE project: validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors","volume":"26","author":"West","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2016.08.026_b0165","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/gm268","article-title":"Genetics and genomics of radiotherapy toxicity: towards prediction","volume":"3","author":"West","year":"2011","journal-title":"Genome Med"},{"key":"10.1016\/j.radonc.2016.08.026_b0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.mrrev.2015.01.001","article-title":"How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models","volume":"764","author":"van Gisbergen","year":"2015","journal-title":"Mutat Res Rev Mutat Res"},{"key":"10.1016\/j.radonc.2016.08.026_b0175","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/ng.3020","article-title":"A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1","volume":"46","author":"Fachal","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.radonc.2016.08.026_b0180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0167-8140(01)00429-7","article-title":"Consequential late effects in normal tissues","volume":"61","author":"D\u00f6rr","year":"2001","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0185","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ijrobp.2012.10.042","article-title":"Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer","volume":"85","author":"Hamstra","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.026_b0190","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.ijrobp.2010.01.069","article-title":"Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model","volume":"78","author":"Tucker","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.026_b0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.radonc.2015.07.027","article-title":"Comparison of two different rectal spacers in prostate cancer external beam radiotherapy in terms of rectal sparing and volume consistency","volume":"116","author":"Wolf","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0200","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2013.05.007","article-title":"Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach","volume":"107","author":"Langendijk","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.026_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2016.01.006","article-title":"Decision support systems for personalized and participative radiation oncology","author":"Lambin","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.radonc.2016.08.026_b0210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.radonc.2015.12.029","article-title":"Development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer - Comparison of dose, toxicity and cost-effectiveness","volume":"118","author":"Cheng","year":"2016","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814016342906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814016342906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T10:59:20Z","timestamp":1536404360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814016342906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0167814016342906"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2016.08.026","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Who will benefit most from hydrogel rectum spacer implantation in prostate cancer radiotherapy? A model-based approach for patient selection","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2016.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}